{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","pValueComment":"Two-sided p-value from log-rank test stratified by EGFR mutation group and race.","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.426","ciPctValue":"95","ciUpperLimit":"0.778","estimateComment":"Afatinib 40 mg versus Pemetrexed/Cisplatin Chemotherapy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","paramType":"Hazard Ratio (HR)","paramValue":"0.576","statisticalComment":"Cox Proportional Hazard (PH) regression stratified by epidermal growth factor receptor (EGFR) mutation group and race.","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.63","upperLimit":"13.70","value":"11.17"},{"groupId":"OG001","lowerLimit":"5.39","upperLimit":"8.25","value":"6.90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"PFS was defined as time from randomisation to disease progression or death whichever occured first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). Median time results from unstratified Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Afatinib monotherapy 40 mg film-coated tablets orally once daily.","id":"OG000","title":"Afatinib 40 mg"},{"description":"Patients received Pemetrexed 500 mg/m\\^2 lyophilised powder as intravenous infusion after Cisplatin 75 mg/m\\^2 solution for infusion as intravenous infusion on Day 1 of each 21-day treatment course up to 6 cycles.","id":"OG001","title":"Pemetrexed/Cisplatin Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Randomised set (RS)","reportingStatus":"POSTED","timeFrame":"Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression","title":"Progression-Free Survival (PFS) Time","type":"PRIMARY","unitOfMeasure":"Months."}